Bioventus Stock Net Income
| BVS Stock | USD 4.55 0.15 3.19% |
Bioventus fundamentals help investors to digest information that contributes to Bioventus' financial success or failures. It also enables traders to predict the movement of Bioventus Stock. The fundamental analysis module provides a way to measure Bioventus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bioventus stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -96.7 M | -91.9 M | |
| Net Income Applicable To Common Shares | 22.3 M | 23.4 M | |
| Net Loss | -203.8 M | -193.6 M | |
| Net Loss | (2.49) | (2.37) | |
| Net Income Per E B T | 1.29 | 1.35 |
Bioventus | Net Income |
Bioventus Company Net Income Analysis
Bioventus' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Bioventus Net Income | (96.74 M) |
Most of Bioventus' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bioventus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bioventus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bioventus is extremely important. It helps to project a fair market value of Bioventus Stock properly, considering its historical fundamentals such as Net Income. Since Bioventus' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bioventus' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bioventus' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bioventus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bioventus reported net income of (96.74 Million). This is 128.35% lower than that of the Health Care Equipment & Supplies sector and 140.63% lower than that of the Health Care industry. The net income for all United States stocks is 116.94% higher than that of the company.
Bioventus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bioventus' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bioventus could also be used in its relative valuation, which is a method of valuing Bioventus by comparing valuation metrics of similar companies.Bioventus is currently under evaluation in net income category among related companies.
Bioventus Current Valuation Drivers
We derive many important indicators used in calculating different scores of Bioventus from analyzing Bioventus' financial statements. These drivers represent accounts that assess Bioventus' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bioventus' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.1B | 1.1B | 862.9M | 160.2M | 330.2M | 313.6M | |
| Enterprise Value | 1.2B | 1.2B | 1.2B | 546.5M | 702.7M | 1.2B |
Bioventus Institutional Holders
Institutional Holdings refers to the ownership stake in Bioventus that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bioventus' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bioventus' value.| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 193.5 K | Marshall Wace Asset Management Ltd | 2023-12-31 | 190.6 K | Charles Schwab Investment Management Inc | 2023-12-31 | 180.5 K | Qube Research & Technologies | 2023-12-31 | 178.5 K | Jane Street Group, Llc | 2023-12-31 | 155.7 K | Stephens Inc | 2023-12-31 | 142.7 K | Renaissance Technologies Corp | 2023-12-31 | 135.2 K | Mariner Wealth Advisors, Llc | 2023-12-31 | 130.6 K | Two Sigma Advisers, Llc | 2023-12-31 | 127.9 K | Essex Woodlands Health Ventures | 2023-12-31 | 13 M | Nantahala Capital Management, Llc | 2023-12-31 | 12 M |
Bioventus Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | 0.0012 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 729.06 M | ||||
| Shares Outstanding | 63.38 M | ||||
| Shares Owned By Insiders | 11.15 % | ||||
| Shares Owned By Institutions | 66.30 % | ||||
| Number Of Shares Shorted | 787.34 K | ||||
| Price To Earning | 6.96 X | ||||
| Price To Book | 2.08 X | ||||
| Price To Sales | 0.57 X | ||||
| Revenue | 512.35 M | ||||
| Gross Profit | 302.71 M | ||||
| EBITDA | 73.38 M | ||||
| Net Income | (96.74 M) | ||||
| Cash And Equivalents | 34.36 M | ||||
| Cash Per Share | 0.56 X | ||||
| Total Debt | 409.48 M | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 0.94 X | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | 15.34 M | ||||
| Short Ratio | 4.43 X | ||||
| Earnings Per Share | (1.54) X | ||||
| Price To Earnings To Growth | 2.14 X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 970 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 295.03 M | ||||
| Total Asset | 810.91 M | ||||
| Retained Earnings | (321.54 M) | ||||
| Working Capital | 92.5 M | ||||
| Net Asset | 810.91 M |
About Bioventus Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bioventus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioventus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioventus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bioventus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bioventus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bioventus will appreciate offsetting losses from the drop in the long position's value.Moving together with Bioventus Stock
| 0.77 | ELMD | Electromed | PairCorr |
| 0.72 | FEMY | Femasys Financial Report 9th of May 2024 | PairCorr |
Moving against Bioventus Stock
| 0.65 | IVP | Inspire Veterinary | PairCorr |
| 0.6 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
| 0.49 | DYNT | Dynatronics Financial Report 9th of May 2024 | PairCorr |
| 0.43 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Bioventus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bioventus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bioventus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bioventus to buy it.
The correlation of Bioventus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bioventus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bioventus moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bioventus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bioventus Piotroski F Score and Bioventus Altman Z Score analysis. For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Bioventus Stock analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Bioventus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioventus. If investors know Bioventus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioventus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 8.178 | Quarterly Revenue Growth 0.076 | Return On Assets 0.0012 | Return On Equity (0.38) |
The market value of Bioventus is measured differently than its book value, which is the value of Bioventus that is recorded on the company's balance sheet. Investors also form their own opinion of Bioventus' value that differs from its market value or its book value, called intrinsic value, which is Bioventus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioventus' market value can be influenced by many factors that don't directly affect Bioventus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioventus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bioventus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioventus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.